ALLO
Allogene Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$1.30
−0.76%Price chart
Sep 18Sep 23Sep 28Oct 1Oct 6Oct 9Oct 14Oct 19
Key dataOct 19, 2026
Open$1.30
From 52W high−57.52%
Volume5.89M
Market cap$449.14M
P/E (TTM)—
P/S (TTM)96.8x
Div yield—
Key dataOct 19, 2026
Open
$1.30
From 52W high
−57.52%
Volume
5.89M
Market cap
$449.14M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−1.2x
P/E (TTM)
—
RSI (14)
26.6
MomentumView details →
1D Return
−0.76%
YTD Return
−4.74%
SummaryUpdated Jun 1, 2026
Allogene Therapeutics, Inc. (NASDAQ:ALLO) is a clinical-stage immuno-oncology biotechnology company founded in 2017 and headquartered in South San Francisco, California. The company went public in October 2018 and has positioned itself as a pioneer in developing "off-the-shelf" allogeneic CAR T cell therapies for cancer treatment and autoimmune diseases. Unlike traditional CAR T therapies that require extracting and modifying a patient's own immune cells, Allogene's approach uses genetically engineered T cells from healthy donors that can be manufactured in advance and stored for immediate use when needed.
Similar companies
Latest newsMore news →
Allogene Therapeutics announced that Chief Financial Officer Geoffrey Parker will retire effective November 6, 2026.47d agoDimensional Fund Advisors LP increased its stake in Allogene Therapeutics, Inc. by 25.5% during the first quarter, acquiring an additional 243,839 shares, according to a 13F filing.68d ago